Study Finds SNAI1 Gene Drives Liver Scarring

Researchers report that blocking the SNAI1 gene reduced liver fibrosis in mice in a study published in Targetome.

Updated on Nov. 16, 2026 in Life Sciences

Bold flat-color editorial illustration of pale ochre cells with rust-brown fibrous strands on a deep teal field, one strand pulled taut.
Researchers reported that blocking the SNAI1 gene reduced liver scarring in mice, a finding that points to a possible target for treating chronic liver disease. AI Illustration. Upload story photo >

Researchers reported that deleting or pharmacologically inhibiting SNAI1 reduced liver fibrosis in mice. A compound called LFW273 lowered SNAI1 levels and reduced liver injury and collagen deposition in the animals.

Why it matters

Liver fibrosis develops when repeated injury from conditions such as chronic viral hepatitis, alcohol-related liver disease or MASH triggers a persistent wound-healing response. Identifying a gene that drives this scarring offers a potential target for future treatments.

The study is preclinical, with results from mice and cultured human cells rather than patients. Whether the findings translate to human MASH or other forms of liver fibrosis has not yet been determined.

The players

China Pharmaceutical University

A university in Nanjing, China, whose researchers led the study on SNAI1 and liver fibrosis.

The details

Researchers analyzed publicly available human liver gene expression data to identify cells expressing SNAI1, then deleted Snai1 in mouse stellate cells and induced liver injury with carbon tetrachloride. SNAI1 expression rose in stellate cells in fibrotic livers, and SNAI1 bound regulatory regions of two scarring genes, ACTA2 and COL1A1.

Timeline

  1. The study was published in Targetome on 11 November 2026.

  2. News-Medical reported on the study on 16 November 2026.

Field Context

The work builds on the established role of hepatic stellate cells as the main source of scar tissue in the liver, and it identifies SNAI1 as a transcription factor within that activation pathway. It adds a candidate target to research aimed at MASH, a condition that has few approved drug options for fibrosis.

Any treatment built on this finding would still need years of testing before reaching patients. For now, the results offer a research direction rather than a change in care for people with liver disease.

The takeaway

Scarring in the liver depends on specific genetic switches, and identifying them can point toward new treatment targets. Readers following liver disease should watch for later human studies before drawing conclusions about therapy.

Further reading

Explore more research in Life Sciences.

More information

Read the full Targetome journal article on SNAI1 and liver fibrosis.

Source note: This article includes information reported by News-Medical.